Drug Profile


Alternative Names: 221149; GSK-221149; GSK-221149A

Latest Information Update: 20 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Indenes; Morpholines; Oxazoles; Piperazines; Small molecules; Tocolytics
  • Mechanism of Action Oxytocin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Preterm labour

Most Recent Events

  • 20 Oct 2017 GlaxoSmithKline terminates a phase III trial in Preterm labour in Israel, Belgium, Germany, South Korea, Italy, Spain, Sweden, France, Mexico due to feasibility of recruiting the study in a timely manner (IV) (NCT02292771)
  • 28 Jun 2017 GlaxoSmithKline terminates phase III trial in Preterm labour (In adolescents, In adults) in USA (IV) (NCT02377466)
  • 01 Feb 2016 Phase-III clinical trials in Preterm labour (In adolescents, In adults) in USA (IV) (NCT02377466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top